Does the adoption of EUCAST susceptibility breakpoints affect the selection of antimicrobials to treat acute community-acquired respiratory tract infections?

[1] Klugman KP(2007)Clinical impact of antibiotic resistance in respiratory tract infections Int J Antimicrob Agents 29 S6-S10

[2] Bartlett JG(2008)Is activity against “atypical” pathogens necessary in the treatment protocols for community-acquired pneumonia? Issues with combination therapy Clin Infect Dis 1;47 S232-S236

[3] Esposito S(2008)Role of atypical bacteria in children undergoing tonsillectomy because of severely recurrent acute tonsillopharyngitis Eur J Clin Microbiol Infect Dis 27 1233-1237

[4] Marchisio P(2002)Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis Clin Infect Dis 35 113-125

[5] Capaccio P(2005)European Respiratory Society; European Society of Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections Eur Respir J 26 1138-1180

[6] Bellasio M(2007)Infectious Diseases Society of America; American Thoracic Society: Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults Clin Infect Dis 44 S27-S72

[7] Corti F(2011)The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America Clin Infect Dis 53 25-76

[8] Dusi E(1996)Antimicrobial resistance among lower respiratory tract isolates ofStreptococcus pneumoniae: results of a 1992–93 western Europe and USA collaborative surveillance study. The Alexander Project Collaborative Group J Antimicrob Chemother 38 71-84

[9] Blasi F(2002)Resistenza ai farmaci antimicrobici in Streptococcus pneumoniae circolanti nel 1999 in Italia Giorn Ital Microbiol Med Odontoiatrica Clin IV 13-30

[10] Pignataro L(2007)Recent findings from multinational resistance surveys: are we ‘PROTEKTed’ from resistance? Int J Antimicrob Agents 9 S2-S5

[1] Klugman KP(2007)Clinical impact of antibiotic resistance in respiratory tract infections Int J Antimicrob Agents 29 S6-S10

[2] Bartlett JG(2008)Is activity against “atypical” pathogens necessary in the treatment protocols for community-acquired pneumonia? Issues with combination therapy Clin Infect Dis 1;47 S232-S236

[3] Esposito S(2008)Role of atypical bacteria in children undergoing tonsillectomy because of severely recurrent acute tonsillopharyngitis Eur J Clin Microbiol Infect Dis 27 1233-1237

[4] Marchisio P(2002)Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis Clin Infect Dis 35 113-125

[5] Capaccio P(2005)European Respiratory Society; European Society of Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections Eur Respir J 26 1138-1180

[6] Bellasio M(2007)Infectious Diseases Society of America; American Thoracic Society: Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults Clin Infect Dis 44 S27-S72

[7] Corti F(2011)The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America Clin Infect Dis 53 25-76

[8] Dusi E(1996)Antimicrobial resistance among lower respiratory tract isolates ofStreptococcus pneumoniae: results of a 1992–93 western Europe and USA collaborative surveillance study. The Alexander Project Collaborative Group J Antimicrob Chemother 38 71-84

[9] Blasi F(2002)Resistenza ai farmaci antimicrobici in Streptococcus pneumoniae circolanti nel 1999 in Italia Giorn Ital Microbiol Med Odontoiatrica Clin IV 13-30

[10] Pignataro L(2007)Recent findings from multinational resistance surveys: are we ‘PROTEKTed’ from resistance? Int J Antimicrob Agents 9 S2-S5